Clinical Trials Logo

Adult Brain Tumor clinical trials

View clinical trials related to Adult Brain Tumor.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03525080 Completed - Brain Neoplasms Clinical Trials

Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors

GLIROPA
Start date: June 12, 2018
Phase: N/A
Study type: Interventional

For patient having a brain tumor, RMI is the standard exam for tumor characterization and determines initial surgery. The aim of this study is to assess if PET could provide additional information that could have an impact on surgery (indication and planification)

NCT ID: NCT02193568 Completed - Adult Brain Tumor Clinical Trials

Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy

Start date: April 30, 2014
Phase: Phase 4
Study type: Interventional

This randomized clinical trial studies light sedation compared with intubated general anesthesia (a loss of feeling and a complete loss of awareness that feels like a very deep sleep) in reducing complications and length of hospital stay in patients with brain cancer undergoing craniotomy. Craniotomy is an operation in which a piece of the skull is removed so doctors can remove a brain tumor or abnormal brain tissue. Light sedation allows patients to remain awake during their surgery, while intubated general anesthesia puts patients to sleep. Surgery complication rates may be reduced if intubated general anesthesia is avoided. Additionally, patients not receiving intubated general anesthesia tend to recover more quickly after surgery. It is not yet known whether light sedation is better at reducing complications and length of hospital stay compared to intubated general anesthesia.

NCT ID: NCT01738646 Completed - Malignant Glioma Clinical Trials

Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients

Start date: January 2013
Phase: Phase 2
Study type: Interventional

It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both chemotherapy and anti-angiogenics. Patients will be treated with a combination of bevacizumab and vorinostat.

NCT ID: NCT01172964 Completed - Adult Glioblastoma Clinical Trials

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

Start date: August 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Genetically-modified neural stem cells (NSCs) that convert 5-fluorocytosine (5-FC) into the chemotherapy agent 5-FU (fluorouracil) at sites of tumor in the brain may be an effective treatment for glioma. PURPOSE: This clinical trial studies genetically-modified NSCs and 5-FC in patients undergoing surgery for recurrent high-grade gliomas.

NCT ID: NCT01024907 Completed - Clinical trials for Recurrent Adult Brain Tumor

Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas

Start date: December 17, 2009
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying the best way to give proton beam radiation therapy and to see how well it works in treating patients with low grade gliomas.

NCT ID: NCT00379080 Completed - Adult Glioblastoma Clinical Trials

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

Start date: January 2007
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of tandutinib and to see how well it works in treating patients with recurrent or progressive glioblastoma.Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.